Takeda Pharmaceutical Statistics
Total Valuation
Takeda Pharmaceutical has a market cap or net worth of $43.50 billion. The enterprise value is $74.36 billion.
Important Dates
The next estimated earnings date is Thursday, October 30, 2025, before market open.
| Earnings Date | Oct 30, 2025 |
| Ex-Dividend Date | Mar 31, 2025 |
Share Statistics
Takeda Pharmaceutical has 1.56 billion shares outstanding. The number of shares has increased by 1.18% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.56B |
| Shares Change (YoY) | +1.18% |
| Shares Change (QoQ) | +0.42% |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | 47.43% |
| Float | 1.51B |
Valuation Ratios
The trailing PE ratio is 23.29 and the forward PE ratio is 24.34.
| PE Ratio | 23.29 |
| Forward PE | 24.34 |
| PS Ratio | 1.40 |
| Forward PS | 0.01 |
| PB Ratio | 0.91 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 7.29 |
| P/OCF Ratio | 5.69 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 8.80, with an EV/FCF ratio of 12.47.
| EV / Earnings | 78.35 |
| EV / Sales | 2.39 |
| EV / EBITDA | 8.80 |
| EV / EBIT | 19.18 |
| EV / FCF | 12.47 |
Financial Position
The company has a current ratio of 1.16, with a Debt / Equity ratio of 0.73.
| Current Ratio | 1.16 |
| Quick Ratio | 0.47 |
| Debt / Equity | 0.73 |
| Debt / EBITDA | 3.97 |
| Debt / FCF | 5.86 |
| Interest Coverage | 4.20 |
Financial Efficiency
Return on equity (ROE) is 1.87% and return on invested capital (ROIC) is 2.71%.
| Return on Equity (ROE) | 1.87% |
| Return on Assets (ROA) | 2.31% |
| Return on Invested Capital (ROIC) | 2.71% |
| Return on Capital Employed (ROCE) | 4.73% |
| Revenue Per Employee | $654,374 |
| Profits Per Employee | $19,999 |
| Employee Count | 47,455 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 1.25 |
Taxes
In the past 12 months, Takeda Pharmaceutical has paid $360.34 million in taxes.
| Income Tax | 360.34M |
| Effective Tax Rate | 27.49% |
Stock Price Statistics
The stock price has increased by +1.25% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +1.25% |
| 50-Day Moving Average | 14.68 |
| 200-Day Moving Average | 14.56 |
| Relative Strength Index (RSI) | 34.02 |
| Average Volume (20 Days) | 2,739,156 |
Short Selling Information
The latest short interest is 9.30 million, so 0.60% of the outstanding shares have been sold short.
| Short Interest | 9.30M |
| Short Previous Month | 9.37M |
| Short % of Shares Out | 0.60% |
| Short % of Float | 0.62% |
| Short Ratio (days to cover) | 3.50 |
Income Statement
In the last 12 months, Takeda Pharmaceutical had revenue of $31.05 billion and earned $949.04 million in profits. Earnings per share was $0.59.
| Revenue | 31.05B |
| Gross Profit | 20.18B |
| Operating Income | 3.88B |
| Pretax Income | 1.31B |
| Net Income | 949.04M |
| EBITDA | 8.45B |
| EBIT | 3.88B |
| Earnings Per Share (EPS) | $0.59 |
Full Income StatementBalance Sheet
The company has $2.43 billion in cash and $34.94 billion in debt, giving a net cash position of -$32.51 billion or -$20.82 per share.
| Cash & Cash Equivalents | 2.43B |
| Total Debt | 34.94B |
| Net Cash | -32.51B |
| Net Cash Per Share | -$20.82 |
| Equity (Book Value) | 47.59B |
| Book Value Per Share | 30.46 |
| Working Capital | 2.38B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $7.64 billion and capital expenditures -$1.33 billion, giving a free cash flow of $5.97 billion.
| Operating Cash Flow | 7.64B |
| Capital Expenditures | -1.33B |
| Free Cash Flow | 5.97B |
| FCF Per Share | $3.82 |
Full Cash Flow StatementMargins
Gross margin is 64.98%, with operating and profit margins of 12.48% and 3.06%.
| Gross Margin | 64.98% |
| Operating Margin | 12.48% |
| Pretax Margin | 4.22% |
| Profit Margin | 3.06% |
| EBITDA Margin | 27.21% |
| EBIT Margin | 12.48% |
| FCF Margin | 19.21% |
Dividends & Yields
This stock pays an annual dividend of $0.54, which amounts to a dividend yield of 3.94%.
| Dividend Per Share | $0.54 |
| Dividend Yield | 3.94% |
| Dividend Growth (YoY) | 8.72% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 91.86% |
| Buyback Yield | -1.18% |
| Shareholder Yield | 2.76% |
| Earnings Yield | 2.18% |
| FCF Yield | 13.71% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Takeda Pharmaceutical has an Altman Z-Score of 1.16 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.16 |
| Piotroski F-Score | 6 |
